For research use only. Not suitable for human use.
Isotype
Human IgG
Clonality
Monoclonal Antibody
Description of Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade
About Sotrovimab biosimilar
Sotrovimab is a neutralizing monoclonal antibody with an activity against SARS-CoV-2 virus in humans. It has been commercialized as XEVUDY by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is able to bind with Spike protein, which is responsible of the pathogenicity of the Severe Acute Respiratory Syndrome- Coronavirus( SARS-CoV-2).
A treatment by biosimilar recently approved
FDA and EMA have very recently given their approvals for the marketing of Sotrovimab as a treatment against some severe forms of COVID. The epitope targeted by this neutralizing antibody is not mutated in the different variants of SARS-CoV-2 of concern.
About Spike protein
Spike glycoprotein is a transmembrane viral fusion protein. It is known to be paramount in the binding of the virus to the cell during infection process. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
A research grade biosimilar
Sotrovimab biosimilar is a dual-action antibody, which is able to to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs. Proteogenix offers this product for research use only. Sotrovimab is a human-origin monoclonal antibody expressed in a mammalian system (Chinese Hamster Ovaries-CHO).
Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3,Hang Ma, Chien-Te K. Tseng, Huifang Zong, Yunji Liao, et al., bioRxiv 2022.02.25.482049; doi: https://doi.org/10.1101/2022.02.25.482049
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike, Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens, bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
Fiedler, S., Devenish, S.R.A., Morgunov, A.S. et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Sci Rep 12, 19791 (2022). https://doi.org/10.1038/s41598-022-22214-z
Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168
De Cae, S., Van Molle, I., van Schie, L. et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat Commun 16, 5040 (2025). https://doi.org/10.1038/s41467-025-60250-1
Reviews
Rated 3 out of 5
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody did not show weak inhibition of all variants tested (IC50 344.03 ng/mL for Delta, >500 ng/mL for Gamma and Alpha, 244.1 ng/mL for the wild type).
![CoV-S[679-833]](https://us.proteogenix.science/wp-content/themes/proteogenix/dist/stacks/shop/assets/icons/category/Antigen-BUEXl17m.svg){kind=icon}
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody did not show weak inhibition of all variants tested (IC50 344.03 ng/mL for Delta, >500 ng/mL for Gamma and Alpha, 244.1 ng/mL for the wild type).